Citations

Citations to this article as recorded by  

• Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis
  Maria I. Timanovskaia, Oleg V. Knyzev, Asfold I. Parfenov
  Terapevticheskii arkhiv.2025; 97(2): 145.     CrossRef
• Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
  Jiyoung Yoon, Seung Wook Hong, Kyung-Do Han, Seung-Woo Lee, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim, Hyuk Yoon
  Gut and Liver.2024; 18(3): 489.     CrossRef
• Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience
  Thomas W. J. Huizinga, Valeria Dipasquale, Markus Zabransky, Jens Heyn, Claudio Romano
  Expert Opinion on Biological Therapy.2024; 24(7): 615.     CrossRef
• Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
  Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
  Journal of Clinical Gastroenterology.2023; 57(6): 601.     CrossRef
• Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
  Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, Byong Duk Ye, Kyeong Ok Kim, Jeong Eun Shin, Yong Sik Yoon, Hong Sub Lee, Sung Hoon Jung, Miyoung Choi, Soo-Young Na, Chang Hwan Choi, Joo Sung Kim
  Intestinal Research.2023; 21(1): 43.     CrossRef
• Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
  Harpreet Singh, Liam Wilson, Tom Tencer, Jinender Kumar
  ClinicoEconomics and Outcomes Research.2023; Volume 15: 125.     CrossRef
• PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
  Christine Martinez-Vinson, Anaïs Lemoine, Yoram Bouhnik, Ben Braithwaite, Audrey Fohlen-Weill, Janet Addison
  Journal of Pediatric Gastroenterology & Nutrition.2023; 76(4): 451.     CrossRef
• Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
  Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber
  Gut and Liver.2023; 17(3): 430.     CrossRef
• Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals
  Quentin Jarrion, Brahim Azzouz, James Robinson, Damien Jolly, Catherine Vallet, Thierry Trenque
  Therapies.2022; 77(4): 467.     CrossRef
• A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST)
  Christopher Wynne, Christian Schwabe, Charlotte Lemech, Heimo Stroissnig, Roshan Dias, Joanna Sobierska, Eric Guenzi, Hendrik Otto, Abid Sattar, Richard Kay, Halimu N. Haliduola, Fausto Berti
  Expert Opinion on Investigational Drugs.2022; 31(9): 965.     CrossRef
• The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)
  Enrique de-Madaria, José J Mira, Irene Carrillo, Waqqas Afif, Daphne Ang, Marina Antelo, Steven Bollipo, Antoni Castells, Prabhleen Chahal, Henriette Heinrich, Joanna K Law, Monique E van Leerdam, Sabela Lens, Rahul Pannala, San Hyoung Park, Atoosa Rabiee
  The Lancet Gastroenterology & Hepatology.2022; 7(5): 485.     CrossRef
• Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
  Jongwook Yu, Hye Kyung Hyun, Jihye Park, Eun Ae Kang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
  Gut and Liver.2022; 16(3): 414.     CrossRef
• Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
  Jan Marsal, Manuel Barreiro-de Acosta, Irina Blumenstein, Maria Cappello, Thomas Bazin, Shaji Sebastian
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Personalized medicine in inflammatory bowel disease: Perspectives on Asia
  Su Hyun Park, Sang Hyoung Park
  Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
• Improving Global Healthcare and Reducing Costs Using Second-Generation Artificial Intelligence-Based Digital Pills: A Market Disruptor
  Yaron Ilan
  International Journal of Environmental Research and Public Health.2021; 18(2): 811.     CrossRef
• Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects
  Kyung‐Sang Yu, In‐Jin Jang, Hyeong‐Seok Lim, Jang Hee Hong, Min‐Gul Kim, Min Kyu Park, Doo‐Yeoun Cho, Min Soo Park, Jae Yong Chung, Jong‐Lyul Ghim, SeungHwan Lee, Seok Kyu Yoon, In Sun Kwon, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Jung Bin Cha, Daniel E
  Clinical and Translational Science.2021; 14(4): 1280.     CrossRef
• Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
  Hyo Yeop Song, Geom Seog Seo
  Journal of the Korean Medical Association.2021; 64(9): 605.     CrossRef
• Intestinal microbiota and inflammatory bowel diseases
  Chang Soo Eun
  Journal of the Korean Medical Association.2021; 64(9): 588.     CrossRef
• Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
  Karen Hanson
  Crohn's & Colitis 360.2021;[Epub]     CrossRef
• Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
  Anna Pękala, Rafał Filip
  Journal of Clinical Medicine.2021; 10(22): 5311.     CrossRef